Have a feature idea you'd love to see implemented?
Let us know!
BPMC Blueprint Medicines Corp
Price (delayed)
$96.62
Market cap
$6.14B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.06
Enterprise value
$6.51B
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company
Highlights
BPMC's gross profit has surged by 114% year-on-year and by 21% since the previous quarter
Blueprint Medicines's revenue has surged by 101% YoY and by 20% QoQ
Blueprint Medicines's equity has surged by 55% YoY but it has decreased by 2.2% QoQ
BPMC's debt is up by 41% year-on-year
BPMC's quick ratio is down by 19% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of BPMC
Market
Valuations
Earnings
Shares outstanding
63.53M
Market cap
$6.14B
Enterprise value
$6.51B
Price to earnings (P/E)
N/A
Price to book (P/B)
19.54
Price to sales (P/S)
14.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.98
Revenue
$434.41M
EBIT
-$101.89M
EBITDA
-$78.34M
Free cash flow
-$250.52M
Per share
Balance sheet
Liquidity
EPS
-$2.06
Free cash flow per share
-$3.95
Book value per share
$4.94
Revenue per share
$6.85
TBVPS
$18.93
Total assets
$1.2B
Total liabilities
$886.5M
Debt
$471.5M
Equity
$313.15M
Working capital
$597.19M
Debt to equity
1.51
Current ratio
3.32
Quick ratio
3.15
Net debt/EBITDA
-4.73
Margins
Efficiency
Dividend
EBITDA margin
-18%
Gross margin
97%
Net margin
-29.5%
Operating margin
-63.5%
Return on assets
-11.4%
Return on equity
-47.7%
Return on invested capital
-8.5%
Return on capital employed
-10.8%
Return on sales
-23.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BPMC stock price
How has the Blueprint Medicines stock price performed over time
Intraday
1.91%
1 week
1.01%
1 month
12.86%
1 year
45.73%
YTD
4.75%
QTD
4.45%
Financial performance
How have Blueprint Medicines's revenue and profit performed over time
Revenue
$434.41M
Gross profit
$421.48M
Operating income
-$275.95M
Net income
-$128.05M
Gross margin
97%
Net margin
-29.5%
BPMC's gross profit has surged by 114% year-on-year and by 21% since the previous quarter
Blueprint Medicines's revenue has surged by 101% YoY and by 20% QoQ
BPMC's net margin has soared by 89% year-on-year and by 48% since the previous quarter
The net income has soared by 77% YoY and by 38% QoQ
Growth
What is Blueprint Medicines's growth rate over time
Valuation
What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
19.54
P/S
14.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.98
Blueprint Medicines's EPS has surged by 78% YoY and by 39% QoQ
The price to book (P/B) is 93% higher than the 5-year quarterly average of 10.1 but 23% lower than the last 4 quarters average of 25.4
Blueprint Medicines's equity has surged by 55% YoY but it has decreased by 2.2% QoQ
Blueprint Medicines's revenue has surged by 101% YoY and by 20% QoQ
The P/S is 38% below the 5-year quarterly average of 22.6 and 25% below the last 4 quarters average of 18.8
Efficiency
How efficient is Blueprint Medicines business performance
Blueprint Medicines's return on sales has surged by 90% YoY and by 53% QoQ
The ROIC has soared by 81% YoY and by 46% from the previous quarter
The company's return on assets has surged by 75% YoY and by 39% QoQ
BPMC's return on equity has surged by 69% year-on-year and by 44% since the previous quarter
Dividends
What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BPMC.
Financial health
How did Blueprint Medicines financials performed over time
BPMC's total assets is 35% greater than its total liabilities
Blueprint Medicines's current ratio has decreased by 19% YoY and by 11% from the previous quarter
BPMC's quick ratio is down by 19% year-on-year and by 11% since the previous quarter
BPMC's debt is 51% greater than its equity
Blueprint Medicines's equity has surged by 55% YoY but it has decreased by 2.2% QoQ
BPMC's debt is up by 41% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.